

NeoNavia commercial version fully integrated according to plan

NeoDynamics commercialization of its innovative biopsy system NeoNavia is progressing according to plan. The development team has received the awaited fully integrated biopsy system prototypes and the final evaluation and optimization is now well under way.

— Leaving the prototype phase and initiating the final evaluation and optimization of our biopsy system is an extremely important and satisfying milestone. This is the last phase prior to initiating formal verification and validation activities needed to complete all technical documentation for requesting regulatory clearance for market access, says Magnus Olsen, Chief Development & Operations Officer, NeoDynamics.

— We are very happy to be a strategic partner to NeoDynamics. They have put trust in us for establishing and acting as their development organization, where we are involved in projects from idea conception to finished product. Etteplan has the privilege to support NeoDynamics with specialist knowledge in our core competence areas of product development and medical technology. To us it is extremely exciting and rewarding taking part in developing these products that can truly make a difference for so many people, says Mikael Vatn, Senior Vice President, Central and Western Europe, Etteplan.

— Sanmina is proud to be one of NeoDynamics development and manufacturing partners for their highly innovative biopsy system which uses micropulse technology. Tord Berggren, Vice President Operations of Sanmina, Örnsköldsvik.

For further information about NeoDynamics, please contact:

Anna Eriksrud, CEO

Telephone: +46 8 522 79 667

E-mail: anna.eriksrud@neodynamics.se

or:

Jörgen Vrenning, CFO/Investor Relations

jorgen.vrenning@neodynamics.se

Telephone: +46 708 519648

About NeoDynamics

Every year, approximately 2.1 million women worldwide are diagnosed with breast cancer, increasing by five percent per year. NeoDynamics has developed the NeoNavia® biopsy system which facilitates and improves tissue sampling (biopsies) in breast cancer patients, with a new patented micropulse technology. This method gives precision and control. In close collaboration with leading clinicians, we have gained experience of having used the technology in more than 300 procedures at around 15 university hospitals across Europe. NeoDynamics is currently completing development of the commercial version of NeoNavia. Among several design and usability features it integrates micropulse technology with multiple needle options for maximum versatility. NeoNavia is expected to be launched towards the end of 2019 in a breast biopsy market worth approximately USD 500 million per year. The technology is likewise suited for cancer diagnostics in other organs such as prostate, lung, kidney and liver.